Form 4: Venture Capital Group Converts Over 5.6 Million Shares of CARLSMED Preferred Stock to Common Ahead of IPO

Presidio Management Group XII and affiliated entities converted 5,642,073 shares of CARLSMED, Inc. preferred stock into common stock, signaling a significant step towards the company's anticipated initial public offering.

Summary

• Presidio Management Group XII, L.L.C., U.S. Venture Partners XII, L.P., and Casey M. Tansey, identified as a Director and 10% Owner of CARLSMED, Inc., reported a conversion of preferred stock into common stock.
• The transaction occurred on July 24, 2025.
• A total of 5,642,073 shares of common stock were acquired through the conversion of various series of preferred stock (Series A, B, and C).
• This conversion follows a 1-for-5.58 reverse stock split of CARLSMED's common and preferred stock, which was effective on July 10, 2025.
• Each share of preferred stock is convertible into one share of common stock immediately prior to the closing of CARLSMED's initial public offering, with no additional consideration and no expiration date.
• Following these transactions, the reporting persons beneficially own a total of 5,642,073 shares of common stock indirectly through various U.S. Venture Partners funds.

Sentiment

Score: 5

Explanation: The filing reports a procedural conversion of preferred stock to common stock, which is a neutral event in itself but signals progress towards a potential IPO. It does not contain inherently positive or negative financial performance data.

Positives

• Conversion of preferred stock to common stock is a necessary step for an initial public offering (IPO), indicating progress towards a liquidity event for the company and its early investors.
• The transaction consolidates a significant block of shares (5,642,073 common shares) under the reporting entities, demonstrating continued substantial ownership by key venture capital investors.

Negatives

• No inherently negative aspects are directly reported in this procedural filing.

Risks

• No specific risks are detailed in this Form 4 filing.

Future Outlook

The filing indicates that the conversion of preferred stock into common stock is a prerequisite for CARLSMED, Inc.'s initial public offering (IPO), suggesting that an IPO is anticipated in the near future.

Industry Context

This type of preferred stock conversion by venture capital investors is a standard procedural step often undertaken by private companies as they prepare for an initial public offering (IPO). It consolidates various classes of preferred equity into a single class of common stock, simplifying the capital structure for public trading.

Comparison to Industry Standards

• This conversion aligns with typical pre-IPO activities observed in the venture capital and technology/biotech sectors.
• Companies like Palantir Technologies (PLTR) and Snowflake (SNOW) also underwent similar capital structure simplifications, including preferred stock conversions, prior to their direct listings or IPOs.
• The 1-for-5.58 reverse stock split is also a common maneuver to adjust share price and share count to be more appealing to public market investors, similar to actions taken by companies like Beyond Meat (BYND) or Peloton (PTON) in their pre-IPO stages.

Related Party Transactions

• The reported transactions involve the conversion of preferred stock by entities identified as a Director and 10% Owner of CARLSMED, Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Existing common shareholders will see an increase in the number of common shares outstanding due to the conversion, potentially impacting per-share metrics. The anticipated IPO could provide liquidity and a market valuation for their holdings.
• Potential Investors: The conversion and reverse split streamline the capital structure, making the company more appealing and understandable for potential public market investors.
• Employees: An IPO could lead to increased valuation of employee stock options and equity grants.

Next Steps

• Anticipated initial public offering (IPO) for CARLSMED, Inc.

Key Dates

Keywords

CARLSMED, SEC Form 4, Beneficial Ownership, Preferred Stock Conversion, Common Stock, Initial Public Offering (IPO), Venture Capital, Insider Transaction, Stock Split, CARL